Adult and children dose of phenetoin

Phenytoin dosing (quick answer):

Adults: Loading dose 15-20 mg/kg IV (max 50 mg/min), maintenance 300 mg/day (or 4-7 mg/kg/day) in 1-3 divided doses
Children: Loading dose 15-20 mg/kg IV, maintenance 4-8 mg/kg/day divided every 8-12 hours
Therapeutic serum level: 10-20 mcg/mL

Searching sources...

Reading File

Finding Sources

Searching the Web

phenytoin adult pediatric dosing loading maintenance 2024

Reading File

Finding Sources

Reading File

Finding Sources

Now I have comprehensive data from the Harriet Lane Handbook, FDA labeling, and the Family Medicine textbook. Here is the full, detailed answer:

Phenytoin Dosing

ADULTS

Status Epilepticus (IV)

Parameter	Dose
Loading dose	10-20 mg/kg IV (usual 15-20 mg/kg)
Max infusion rate	50 mg/min (slower if elderly or cardiac risk)
Maintenance dose	100 mg IV/oral every 6-8 hours

Non-emergent Loading & Maintenance (IV/Oral)

Parameter	Dose
Loading dose (oral, hospitalized)	1000 mg divided as 400 mg, then 300 mg, then 300 mg q2h
Loading dose (IV)	10-15 mg/kg IV at max 50 mg/min
Maintenance (oral capsules)	100 mg 3 times daily (300 mg/day) or 300 mg once daily
Maintenance (IV)	100 mg IV every 6-8 hours
Range	200-500 mg/day, adjusted by levels

Oral Maintenance by Weight

4-7 mg/kg/day in 1-3 divided doses (adjusted to therapeutic level)

CHILDREN (Pediatric)

Status Epilepticus (IV)

Age	Loading Dose	Max Infusion Rate
All pediatric ages	15-20 mg/kg IV	1-3 mg/kg/min or 50 mg/min (whichever is slower)

Maintenance Dose (Oral or IV)

Age Group	Dose
Neonates	5 mg/kg/day divided q12h
Infants/Children < 6 years	5 mg/kg/day in 2-3 divided doses (max 300 mg/day)
Children > 6 years	7.5-9 mg/kg/day in 2-3 divided doses
Adolescents	300 mg/day (same as adult)

Children generally require higher mg/kg doses than adults due to faster hepatic metabolism.

NEONATAL DOSING (from Harriet Lane Handbook)

Loading dose: 15-20 mg/kg IV
Maintenance: 5 mg/kg/day divided every 12 hours
Rate: not to exceed 1-3 mg/kg/min

Therapeutic Drug Monitoring

Level	Target
Total phenytoin	10-20 mcg/mL (mg/L)
Free (unbound) phenytoin	1-2 mcg/mL

Monitor free levels in: hypoalbuminemia, renal failure, pregnancy, elderly patients (reduced protein binding)

Key Practical Points

Non-linear (Michaelis-Menten) kinetics: Small dose increases near the therapeutic range can cause disproportionately large rises in serum levels - dose changes should be small (25-50 mg increments)
IV rate warning: Rapid IV infusion causes hypotension, bradycardia, and cardiac arrhythmias - always monitor ECG and BP
IM route: NOT recommended (painful, erratic absorption, crystal precipitation)
Oral bioavailability: Capsules (sodium salt) and tablets/suspension (acid form) are NOT interchangeable mg-for-mg - 100 mg capsule ≈ 92 mg free acid
Drug interactions: Numerous - enzyme inducer (CYP2C9, CYP3A4); levels altered by carbamazepine, valproate, fluconazole, and many others
Fosphenytoin (prodrug): Dosed in phenytoin sodium equivalents (PE); can be given faster IV (150 mg PE/min in adults) and can be given IM

Sources

The Harriet Lane Handbook, 23rd ed., p. 1888-1904 (pediatric/neonatal dosing)
Textbook of Family Medicine, 9th ed., Table 41-12
FDA Dilantin Label
Drugs.com Phenytoin Dosage Guide (reviewed Mar 2026)

Status epilepticus

Status epilepticus (quick answer):

Status epilepticus (SE) is a seizure lasting >5 minutes OR two or more seizures without recovery of consciousness between them. It is a neurological emergency requiring immediate treatment. Management follows a time-based protocol: benzodiazepines first (0-5 min), then second-line IV antiepileptics (5-20 min), then anesthetic agents if refractory (>30-40 min).

Searching sources...

Finding Sources

Searching the Web

status epilepticus management guidelines 2024 2025

Reading File

Loading Image

Here is a complete, evidence-based overview of Status Epilepticus:

Status Epilepticus

Definition

A seizure lasting ≥5 minutes OR two or more seizures without recovery of consciousness between them. After 5 minutes, seizures are unlikely to self-terminate, are harder to control with antiepileptics, and begin causing neuronal damage. This is a neurological emergency - treatment should begin immediately.

After 20 minutes: hypotension, hypoxia, metabolic acidosis, hyperthermia, hypoglycemia, cardiac dysrhythmias, and pulmonary edema commonly develop.

Classification

Type	Description
Convulsive SE	Tonic-clonic motor activity with altered consciousness
Nonconvulsive SE (NCSE)	Comatose or fluctuating mental status, no overt seizures - diagnosed by EEG
Refractory SE	Persists despite adequate doses of two antiepileptic agents (>60 min)
Super-refractory SE	Continues or recurs ≥24h after general anaesthetic agent initiation

Common Causes

Subtherapeutic antiepileptic drug levels (most common in known epileptics)
Acute stroke or CNS injury
Anoxia / hypoxia
Metabolic abnormalities (hypoglycemia, hyponatremia, hypocalcemia)
Alcohol or drug intoxication / withdrawal
CNS infections (meningitis, encephalitis)
Preexisting neurologic conditions

Immediate Stabilization (0-5 min)

Airway: Position to maximize ventilation, prevent aspiration; nasopharyngeal airway if needed; consider intubation if prolonged
Breathing: O2 by mask/nasal cannula; bag-valve-mask if inadequate ventilation
Circulation: Large-bore IV access; cardiac monitor, pulse oximetry, BP monitoring
Glucose: Bedside glucose immediately; give IV dextrose if hypoglycemic
Labs: Electrolytes, calcium, magnesium, glucose, renal/liver function, CBC, toxicology screen, antiepileptic drug levels, pregnancy test (if applicable)
Temperature: Monitor continuously; treat hyperthermia with cooling
Do NOT perform LP during active SE; delay CT scan until seizures controlled

Treatment Algorithm

Phase 1 - First-Line: Benzodiazepines (0-10 min)

Terminate seizures 70% of the time. Give as early as possible - delays >10 min increase mortality, seizure duration, and complications.

Drug	Adult Dose	Pediatric Dose	Route
Lorazepam (preferred if IV available)	2-4 mg IV (0.1 mg/kg); repeat once in 5 min	0.05-0.1 mg/kg IV	IV
Midazolam (preferred if no IV access)	10 mg IM/IN	0.2 mg/kg IM; 0.3 mg/kg IN	IM, IN, IV
Diazepam	5-10 mg IV; repeat q5 min (max 30 mg)	0.2-0.5 mg/kg IV (max 10 mg) or 0.5 mg/kg rectal	IV, rectal

Lorazepam: onset 3 min, duration 12-24 hours (preferred IV agent)
Diazepam: onset 2 min, duration only 15-60 min (shorter - seizures may recur)
IM midazolam = as effective as IV lorazepam in pre-hospital trials; preferred when no IV access
Give second benzodiazepine dose only after 5 min of continued seizure activity after first dose

Phase 2 - Second-Line Antiepileptics (start within 20 min)

Start simultaneously with or immediately after benzodiazepines. No single agent is definitively superior.

Drug	Adult Dose	Infusion Rate	Notes
Fosphenytoin (preferred over phenytoin)	20 mg PE/kg IV	up to 150 mg PE/min	Can give IM; fewer cardiac/infusion side effects
Phenytoin	20 mg/kg IV	max 50 mg/min (25 mg/min safer)	Not in glucose solutions; cardiac monitor mandatory
Levetiracetam	20-60 mg/kg IV (typically 2000-4500 mg)	over 15 min	Fewest side effects, no interactions; rapidly gaining favor
Valproic acid	20-40 mg/kg IV	3-6 mg/kg/min	Contraindicated in liver disease, thrombocytopenia, suspected metabolic disease; not with phenytoin
Lacosamide	200-400 mg IV	over 15 min	Alternative with limited data

Phase 3 - Refractory SE: Anesthetic Infusions (<30-60 min target)

Requires intubation, Neuro ICU admission, and continuous EEG monitoring.

Drug	Loading Dose	Infusion Rate
Midazolam	0.2 mg/kg IV	0.05-2 mg/kg/h, titrate to seizure cessation
Propofol	1 mg/kg IV	1-10 mg/kg/h (risk of propofol infusion syndrome at >40 mg/kg/h)
Phenobarbital	20 mg/kg IV	50-75 mg/min
Ketamine	-	5 mg/kg/h infusion (emerging evidence)
Pentobarbital	5-15 mg/kg	0.5-5 mg/kg/h

Pediatric-Specific Notes (Harriet Lane Handbook)

Diazepam IV: Neonate: 0.1-0.3 mg/kg q15-30 min (max 2 mg); Child <5 yr: 0.2-0.5 mg/dose q2-5 min (max 5 mg); Child ≥5 yr: 1 mg/dose q2-5 min (max 10 mg)
Rectal diazepam: 0.5 mg/kg; widely used by EMS in children
Buccal midazolam: 0.5 mg/kg (max 10 mg) - more effective than rectal diazepam in children
Children metabolize antiepileptics faster - weight-based dosing is essential

Nonconvulsive SE - Key Points

Suspect in: prolonged postictal state, subtle motor signs (twitching, eye deviation, blinking), unexplained coma or confusion
Diagnosis requires EEG
Treat similarly to convulsive SE once diagnosed

Prognosis

Mortality increases with:

Delayed diagnosis/treatment
Age >60 years
No prior seizure history
Nonconvulsive SE (often missed)
Underlying etiology severity

Sources:

Tintinalli's Emergency Medicine, 9th ed., Ch. 171 (primary)
Rosen's Emergency Medicine, 9th ed., Ch. 169
Harriet Lane Handbook, 23rd ed. (pediatric dosing)
2025 Surgical Critical Care SE Management Guidelines
ENLS Status Epilepticus Protocol v6.0, July 2024

Barbiturates

Barbiturates (quick answer):

Barbiturates are CNS depressants that act by enhancing GABA-A receptor activity (prolonging Cl⁻ channel opening duration). They range from ultra-short acting (thiopental - anesthesia) to long-acting (phenobarbital - epilepsy). Largely replaced by benzodiazepines due to narrow therapeutic index and high abuse potential, but still used for refractory SE, anesthesia induction, and raised ICP.

Searching sources...

Finding Sources

Searching the Web

barbiturates pharmacology classification mechanism uses 2024

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Excellent data collected from multiple authoritative sources. Here is the complete overview:

Barbiturates

History & Overview

Barbiturates are synthetic CNS depressants derived from barbituric acid (malonic acid + urea). The first, barbital (Veronal), was introduced in 1903. They were once the most widely used sedative-hypnotics but have been largely replaced by benzodiazepines due to their narrow therapeutic index, high abuse potential, and severe toxicity in overdose.

Mechanism of Action

Barbiturates act at the GABA-A receptor - benzodiazepine receptor - chloride ion channel complex:

Drug	GABA-A Effect
Benzodiazepines	Increase the frequency of Cl⁻ channel opening
Barbiturates	Increase the duration of Cl⁻ channel opening

At high/toxic doses, barbiturates can directly activate the chloride channel even without GABA - this explains their greater danger in overdose compared to benzodiazepines.

Additional mechanisms:

Inhibit NMDA and AMPA receptors (glutamate antagonism)
Reduce cerebral metabolic rate (CMRO2) and cerebral blood flow (CBF) - up to 50% reduction at burst-suppression doses
Potent hepatic CYP450 enzyme inducers (accelerate metabolism of many drugs and themselves)

Classification by Duration of Action

Class	Drug	Onset	Duration	Half-life	Key Uses
Ultra-short	Thiopental (Pentothal)	5-15 min	1-4 h	6-46 h	Anesthesia induction, refractory SE, raised ICP
Ultra-short	Methohexital (Brevital)	~1 min	<15 min	3-6 h	ECT anesthesia
Short	Secobarbital (Seconal)	10-15 min	3-4 h	15-40 h	Formerly insomnia
Intermediate	Pentobarbital (Nembutal)	10-48 min	3-4 h	15-50 h	Refractory SE (barbiturate coma), raised ICP, euthanasia
Intermediate	Amobarbital (Amytal)	60 min (oral)	10-12 h	8-42 h	Narcoanalysis, Wada test
Intermediate	Butalbital	45-60 min	6-8 h	34-42 h	Tension headache (combined preparation)
Long	Phenobarbital (Luminal)	60-120 min	10-12 h	80-120 h	Epilepsy, febrile seizures, alcohol withdrawal
Long	Primidone	-	-	-	Epilepsy (converted to phenobarbital)

Therapeutic Indications

1. Epilepsy / Seizures

Phenobarbital: Drug of choice for neonatal seizures; used for generalized tonic-clonic and partial seizures
- Dose: 1-3 mg/kg/day oral; 10-20 mg/kg IV for status epilepticus (max 50-75 mg/min)
Phenobarbital for SE (refractory): 20 mg/kg IV at 50-75 mg/min - third-line after benzodiazepines and second-line agents

2. Anesthesia

Thiopental: Classic IV induction agent (3-5 mg/kg); reduces ICP; used in RSI when propofol unavailable
Methohexital: Preferred for ECT anesthesia (0.7-1.2 mg/kg IV); rapid onset/offset, low cardiac risk

3. Raised ICP / Barbiturate Coma

Pentobarbital coma: Loading 10-15 mg/kg IV, then 1-4 mg/kg/hr infusion
Reduces CMRO2 and CBF up to 50%; used in refractory intracranial hypertension after TBI
Requires continuous EEG monitoring (target: burst suppression)

4. Alcohol Withdrawal / Sedative Withdrawal

Phenobarbital (up to 1500-2000 mg/day) for alcohol withdrawal delirium as alternative to benzodiazepines
Cross-tolerance with benzodiazepines and alcohol via shared GABA-A mechanism
Barbiturate tolerance test: 200 mg pentobarbital or 30-100 mg phenobarbital test dose to assess tolerance level

5. Narcoanalysis / Wada Test

Amobarbital (Amytal interview): IV 50 mg/min up to 500 mg - used for diagnosis of conversion disorder, mutism, malingering
Wada test: Intracarotid amobarbital 100-200 mg to determine language/memory lateralization before epilepsy surgery

6. Preoperative Sedation / Anxiolysis

Short-/intermediate-acting agents used historically; largely replaced now

Pharmacokinetics

Parameter	Details
Absorption	Well absorbed orally
Protein binding	High (variable by agent)
Lipid solubility	Higher lipid solubility = faster onset, shorter action (thiopental > phenobarbital)
Metabolism	Hepatic (CYP450 - and barbiturates induce their own metabolism = autoinduction)
Excretion	Renal
pH effect	Urinary alkalinization increases phenobarbital excretion (used in overdose management)

Adverse Effects

System	Effects
CNS	Sedation, confusion, ataxia, nystagmus, dysarthria, paradoxical excitement (especially in elderly/children)
Respiratory	Dose-dependent respiratory depression - the primary danger; can progress to apnea
Cardiovascular	Hypotension, bradycardia (especially with IV administration)
Tolerance/Dependence	Develops rapidly; physical and psychological dependence
Withdrawal	Severe - can be fatal; seizures, delirium, hyperthermia (worse than benzodiazepine withdrawal)
Rare	Stevens-Johnson syndrome, megaloblastic anemia, neutropenia

Overdose / Toxicity

1 g (10 standard tablets) = serious toxicity; 2-10 g can be fatal

Clinical features:

Dysarthria, ataxia, incoordination
CNS depression → coma
Respiratory depression → respiratory acidosis → apnea (primary cause of death)
Cheyne-Stokes respiration
Hypotension, hypothermia, tachycardia
Miosis, hyporeflexia/areflexia, oliguria

Management:

Airway, ventilation - intubate if needed (no specific antidote)
Activated charcoal (if airway protected, early presentation)
Gastric lavage if very recent ingestion
IV fluids + vasopressors for hypotension
Urinary alkalinization (sodium bicarbonate) - increases phenobarbital renal excretion
Forced diuresis if renal function intact
Hemodialysis in severe cases

Contraindications

Acute intermittent porphyria (barbiturates precipitate acute attacks - absolute contraindication)
Impaired respiratory drive or limited respiratory reserve
Severe hepatic impairment
Pregnancy (teratogenic)
History of substance abuse (relative)

Drug Interactions (CYP450 Induction)

Barbiturates induce CYP450 enzymes, reducing levels of many drugs:

Anticoagulants (warfarin)
Oral contraceptives
Corticosteroids
Antiepileptics (carbamazepine, phenytoin)
Antidepressants, antipsychotics
Opioids, antibiotics, antiarrhythmics, immunosuppressants

Barbiturates vs. Benzodiazepines

Feature	Barbiturates	Benzodiazepines
GABA-A effect	Increase Cl⁻ channel duration	Increase Cl⁻ channel frequency
Therapeutic index	Narrow	Wide
Overdose fatality	Common (no antidote)	Rare alone (flumazenil antidote)
Abuse potential	High	Lower
Dependence	Severe, rapid	Slower
Withdrawal severity	Can be fatal	Rarely fatal
Enzyme induction	Strong CYP450 inducer	Minimal
Clinical use today	Limited	Broad

Sources:

Kaplan & Sadock's Synopsis of Psychiatry (Table 21-48, mechanisms, overdose)
Kaplan & Sadock's Comprehensive Textbook of Psychiatry (Table 33.9a-1, full pharmacokinetic data)
Miller's Anesthesia, 10th ed. (cerebral effects, neuroprotection)
StatPearls - Barbiturates (FDA-approved indications)

Benzodiaxepines

Benzodiazepines (quick answer):

Benzodiazepines (BZDs) are CNS depressants acting on GABA-A receptors - they increase the frequency of Cl⁻ channel opening. They have anxiolytic, sedative-hypnotic, anticonvulsant, muscle relaxant, and amnestic properties. Much safer than barbiturates in overdose (wide therapeutic index), with flumazenil as a specific antidote. Key concern: tolerance, dependence, and potentially dangerous withdrawal.

Searching sources...

Finding Sources

Searching the Web

benzodiazepines pharmacology classification mechanism clinical uses 2024

Finding Sources

Reading File

Finding Sources

Reading File

Excellent - I now have comprehensive data. Here is the full overview:

Benzodiazepines

Overview

Benzodiazepines (BZDs) were first introduced with chlordiazepoxide (Librium) in 1959, followed by diazepam (Valium) in 1963. They rapidly replaced barbiturates as the preferred sedative-hypnotics due to their superior safety profile, wider therapeutic index, and lower abuse potential. They remain one of the most prescribed drug classes worldwide.

Mechanism of Action

BZDs bind to an allosteric site at the junction of the α and γ subunits of the GABA-A receptor, enhancing the inhibitory effect of GABA:

Feature	Benzodiazepines	Barbiturates
GABA-A effect	Increase frequency of Cl⁻ channel opening	Increase duration of Cl⁻ channel opening
Require GABA present?	Yes - only potentiate GABA	No - can directly activate at toxic doses
Ceiling effect?	Yes - cannot open channel without GABA	No - hence greater overdose danger
Therapeutic index	Wide	Narrow

This ceiling effect explains why benzodiazepines alone are rarely lethal in overdose - without GABA present, the chloride channel cannot be opened regardless of dose.

Five pharmacological properties result from this mechanism:

Anxiolytic - reduces anxiety
Sedative-Hypnotic - promotes sleep
Anticonvulsant - raises seizure threshold
Muscle relaxant - via spinal cord and supraspinal effects
Amnestic (anterograde) - blocks formation of new memories

Classification by Duration of Action

Long-Acting (half-life 30-200 hours)

Drug	Brand	Dose Equivalent	Usual Dose (mg/day)	Key Uses
Diazepam	Valium	5 mg	2.5-40	Anxiety, SE, alcohol withdrawal, muscle spasm
Chlordiazepoxide	Librium	10 mg	15-100	Anxiety, alcohol withdrawal
Clonazepam	Klonopin	0.25 mg	0.5-20	Panic disorder, seizures
Clorazepate	Tranxene	7.5 mg	7.5-60	Anxiety, alcohol withdrawal
Flurazepam	Dalmane	15 mg	15-30	Insomnia
Quazepam	Doral	15 mg	7.5-15	Insomnia

Diazepam is metabolized to desmethyldiazepam (t½ >120 h) → then to oxazepam → glucuronidation. Multiple active metabolites extend duration significantly.

Intermediate-Acting (half-life 8-30 hours)

Drug	Brand	Dose Equivalent	Key Uses
Lorazepam	Ativan	1 mg	Anxiety, SE, procedural sedation, alcohol withdrawal
Oxazepam	Serax	15 mg	Anxiety, elderly, hepatic disease
Temazepam	Restoril	15 mg	Insomnia
Estazolam	ProSom	1 mg	Insomnia (6-8 hrs effective)
Alprazolam	Xanax	0.5 mg	Panic disorder, anxiety

Short-Acting (half-life <8 hours)

Drug	Brand	Dose Equivalent	Key Uses
Midazolam	Versed	3 mg	Procedural sedation, anesthesia induction, SE
Triazolam	Halcion	0.25 mg	Insomnia (shortest acting)

Triazolam has the shortest half-life (2-3 hours) - associated with rebound anxiety and anterograde amnesia

Pharmacokinetics - Key Points

Absorption: Oral absorption rapid for diazepam, lorazepam, alprazolam; IM reliable only for lorazepam and midazolam (diazepam IM is erratic)
Lipid solubility: Determines onset and offset after a SINGLE dose
- High lipid solubility (diazepam) = rapid onset, rapid offset after single dose (redistributes quickly out of brain)
- Low lipid solubility (lorazepam) = slower onset, longer single-dose duration (leaves brain slowly)
Protein binding: 70-99% (proportional to lipid solubility)
Metabolism:
- Most: Hepatic oxidation via CYP3A4 and CYP2C19 → active metabolites
- "LOT" drugs (Lorazepam, Oxazepam, Temazepam): direct glucuronidation - NO active metabolites - preferred in elderly, hepatic disease
Active metabolites: Diazepam → desmethyldiazepam (t½ >120h) → oxazepam; flurazepam → desalkylflurazepam (t½ >100h)
Steady state may take up to 2 weeks with long-acting agents - toxicity can appear after 7-10 days at a seemingly safe dose

Therapeutic Indications

1. Anxiety Disorders

GAD: Highly effective for short-term relief; SSRIs/SNRIs preferred for chronic treatment; BZDs as adjuncts
Panic disorder: Alprazolam and clonazepam are first-choice BZDs; often co-initiated with SSRIs for first 3-4 weeks
Social phobia, PTSD: Adjunctive role
Acute situational anxiety: Single-dose use (diazepam, alprazolam)

2. Insomnia

Approved hypnotics: Flurazepam, temazepam, quazepam, estazolam, triazolam
Maximum recommended use: 7-10 consecutive days (investigate underlying cause if longer needed)
Temazepam or estazolam: reasonable compromise for most adults
Avoid flurazepam in elderly (daytime cognitive impairment), triazolam (rebound anxiety, amnesia)

3. Seizures / Status Epilepticus

First-line treatment for SE: Lorazepam IV (2-4 mg), diazepam IV, or midazolam IM/IN
Clonazepam: Chronic anticonvulsant for absence, myoclonic, atonic seizures, panic
Diazepam rectal gel: Used by EMS in children
Buccal midazolam: More effective than rectal diazepam in pediatric SE

4. Alcohol Withdrawal

Gold standard treatment: Diazepam or chlordiazepoxide (long-acting preferred - self-tapering effect)
Lorazepam preferred in hepatic disease (LOT rule - no active metabolites)
Prevent delirium tremens and withdrawal seizures

5. Anesthesia / Procedural Sedation

Midazolam: IV/IM induction agent; anterograde amnesia makes it ideal for procedures
Diazepam: Pre-procedure anxiolysis
Combined with opioids for monitored anesthesia care

6. Muscle Relaxation

Diazepam: Skeletal muscle spasm, spasticity (MS, spinal cord injury), tetanus
Acts via spinal cord interneurons and supraspinal mechanisms

7. Catatonia

Benzodiazepines (especially lorazepam) are the preferred treatment for catatonia

8. Other

Akathisia (adjunct), acute mania (adjunct), ECT premedication, phobias, premenstrual dysphoric disorder (alprazolam)

Adverse Effects

System	Effects
CNS	Sedation, cognitive impairment, psychomotor slowing, anterograde amnesia, ataxia, dysarthria
Respiratory	Respiratory depression (especially with COPD, sleep apnea, elderly); dangerous when combined with opioids/alcohol
Paradoxical reactions	Disinhibition, aggression, excitement, hostility (especially in elderly and children)
Cognitive	Memory impairment, dementia risk with long-term use in elderly
Others	Appetite stimulation/weight gain (alprazolam); teratogenicity (avoid in pregnancy/breastfeeding)

Beers List: All benzodiazepines listed as potentially inappropriate medications in adults ≥65 years

Tolerance, Dependence & Withdrawal

Feature	Details
Tolerance onset	Sedative/hypnotic effects: within days to weeks; anxiolytic effects: slower
Dependence	Physical and psychological; develops with regular use >2-4 weeks
Withdrawal risk	Higher with short-acting agents, high doses, abrupt discontinuation
Short-acting withdrawal	Rapid onset (within 24h), more severe; seizures, delirium may occur
Long-acting withdrawal	Delayed 1-2 weeks, generally milder
Alprazolam	Particularly severe, rapid withdrawal - requires very slow taper

Withdrawal Syndrome features: Anxiety, irritability, insomnia, hyperacusis, nausea, tremor, diaphoresis, restlessness, depersonalization, myoclonus, delirium, seizures

Tapering: Reduce by 25% per week; switch alprazolam to clonazepam (longer half-life) before tapering; carbamazepine 400-500 mg/day may facilitate discontinuation

Overdose / Toxicity

Alone: Rarely fatal due to ceiling effect (no GABA, no channel opening)
With other CNS depressants (alcohol, opioids, barbiturates): Can be fatal - synergistic respiratory depression
Features: Excessive sedation → stupor → respiratory depression → coma
Antidote: Flumazenil (Romazicon) - competitive BZD receptor antagonist
- Dose: 0.2 mg IV, repeat 0.3 mg then 0.5 mg at 1 min intervals; max 3 mg
- Duration: 30-60 min (shorter than most BZDs - resedation can occur)
- Caution: Can precipitate severe acute withdrawal/seizures in BZD-dependent patients

Drug Interactions

Interacting Drug	Outcome
Alcohol, opioids, barbiturates, antihistamines	Dangerous additive CNS/respiratory depression
Lithium, antipsychotics	Ataxia, dysarthria
CYP3A4 inhibitors (azole antifungals, macrolides, grapefruit)	Increased BZD levels → excess sedation
CYP3A4 inducers (rifampicin, carbamazepine)	Reduced BZD levels → reduced efficacy

LOT Rule - Safe in Hepatic Disease / Elderly

Lorazepam, Oxazepam, Temazepam - these three undergo direct glucuronidation only with NO active metabolites, making them safe when CYP450 oxidation is impaired (liver disease, elderly, neonates).

Flumazenil (BZD Antidote)

Mechanism: Competitive antagonist at benzodiazepine receptor
Indications: BZD overdose reversal, reversal of procedural sedation
Onset: 1-2 minutes IV
Duration: 30-60 min (re-dosing often needed)
Contraindications: BZD-dependent patients (precipitates acute withdrawal + seizures); elevated ICP; tricyclic antidepressant co-ingestion (removes seizure protection)

Sources:

Kaplan & Sadock's Synopsis of Psychiatry (Table 21-43, Table 21-44, pharmacokinetics, therapeutic indications, withdrawal)
Miller's Anesthesia, 10th ed. (GABA-A receptor mechanism)
StatPearls - Benzodiazepines

This is a shared conversation. Sign in to Orris to start your own chat.